INSIGHTS ON DRUG DEVELOPMENT

• Developing A Quantitative Surrogate Peptide Assay

  Discover a streamlined LC-MS/MS workflow for Fc-containing therapeutics like dulaglutide to enable precise quantification with LLOQ as low as 1 ng/mL through automated, efficient assay development.

• Increase Throughput For Intact Mass Confirmation And Impurity Screening

  Accelerate intact mass analysis of GLP-1 analogues with automated purity calculations, sub-ppm mass accuracy, and impurity detection for consistent results in under one minute per sample.

• Cell Retention Technology And Specialized Cell Culture Media

  Explore how perfusion technology is transforming upstream bioprocessing by boosting productivity, reducing costs, and enabling process intensification while overcoming cell retention challenges.

• Formulation Strategies For Enabling "Undevelopable" Compounds

  KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.

• Detect Low-Abundance GLP-1 Impurities With Greater Sensitivity

  8/24/2026

  Low-level impurities can be difficult to resolve using conventional approaches. Discover how a Charged Surface 2.3 µm superficially porous Phenyl-Hexyl column enhances reversed-phase LC-MS analysis.

• Right From The Start: Smarter Developability For Stronger Formulations

  2/4/2026

  Early developability assessment integrates manufacturability, QbD, flexible formulations, and CDMO support to cut risk, speed development, and enable scalable, robust drugs.

• Solving Bioavailability Challenges In bRo5 Drugs

  3/20/2026

  Leverage mechanistic, material-sparing formulation strategies to enhance bioavailability and accelerate development of challenging bRo5 small molecules, even with limited resources.

• Ask Us Anything: Cy Credille On Continuity From Discovery To Commercialization

  7/24/2026

  Learn how we balance discovery and development as an asset scales, and how the One Cambrex model keeps the original process scientists attached to a molecule from first kilos through NDA.

• Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up

  9/9/2026

  SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.